REPORT HIGHLIGHT

Assisted reproductive technology (ART) market was valued at USD 22.3 billion by 2019, growing with 9.8% CAGR during the forecast period, 2020-2026.

Assisted Reproductive Technology (ART) is the advanced method used for infertility treatment. The technologies consist of the combination of a woman’s egg and a man’s sperm to develop embryos. ART technology sometimes uses donor sperm, previously frozen embryos of a surrogate or gestational carrier.

Market Dynamics

The increasing prevalence of infertility cases among the couples owing to the rise in pollution, growing consumption of tobacco, smoking, and alcohol is the major factor boosting the global assisted reproductive technology (ART) market growth. As per the recent report by the Indian Journal of Community Medicine Organization, the global infertility cases are increasing at a rapid pace globally and demands immediate attention. The organization also stated that infertility has affected more than 8-10% of couples worldwide. Thus, the demand for ART techniques is increasing among infertile people, supporting industry growth. Furthermore, favorable government initiatives to support ART methods has propelled the market growth. For instance, in February 2020 the Indian government has passed the bill called the Assisted Reproductive Technology Regulation Bill in support of ART treatment methods. This bill intends to regulate ART clinics in the country to provide ethical and safe reproductive procedures.

The emergence of advanced insemination techniques such as intra-cytoplasmic sperm injection (ICSI) for child production is also creating lucrative growth opportunities in the worldwide market. Conversely, lack of professional healthcare, the risk associated with multiple pregnancies, in turn, increases the probability of premature births may hamper the industry growth to a certain extent. However, it is noted that this technology offers astounding benefits than in vitro fertilization which consists of combining eggs and sperm outside the body hence it is safe and has a higher success rate.

Procedure Takeaway

Depending upon the procedure, the worldwide ART market is categorized into fresh non-donor, frozen donor, fresh donor, frozen non-donor, and embryo/egg banking. Of these, the fresh non-donor category accounted for the highest revenue share in 2019. The segment captured over 55% share of the global revenue during the same year. On the contrary, the frozen non-donor segment is likely to grow with promising CAGR during the study period.

Technology Takeaway

In terms of technology, the global market is classified into In-Vitro Fertilization (IVF), and others. IVF category is further divided into IVF without Intracytoplasmic Sperm Injection (ICSI), and IVF with Intracytoplasmic Sperm Injection (ICSI). Out of these, the In-vitro fertilization (IVF) has accounted for the majority of market share in 2019 and is anticipated to witness noteworthy growth during the forecast period. This is mainly due to the highest pregnancy rate provided with safe assistance due to the non-invasive method of child production across the globe. As per the National Center for Biotechnology Information, the IVF method has shown around 40-42% success rate for the maternal age below 40 years.

Regional Takeaway

Regionally, the overall market is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. The growing adoption rate of ART for childbirth coupled with favorable government policies support the growth of this region. As per the Center for Disease Prevention & Control (CDC) data, in 2018, more than 306,197 ART cycles are performed in around 456 U.S. clinics. Thereby, companies are expanding their presence in North America. Recently, in June 2018, FUJIFILM Corporation acquired U.S. based company Irvine Scientific Sales Company, Inc. (ISUS), leading players in cell culture media. This acquisition has helped FUJIFILM to expand its footprint in the U.S. market and to strengthen its product offering in cell therapy and in vitro fertilization segment.

On the contrary, Asia Pacific is anticipated to be the fastest-growing region throughout the forecast period owing to the rising infertility rate in men. The Indian Journal of Community Medicine Organization suggested that in India, around 15 to 20 Million couples are suffering from infertility every year. IVF is one of the most used techniques in this region. However, it is noted that some clinics use less advanced forms of ART, which include zygote intrafallopian transfer (ZIFT), and gamete intrafallopian transfer (GIFT). These techniques are more invasive than IVF and less frequently successful.

COVID-19 Impact

The ART market is adversely affected due to the sudden outbreak of COVID-19 all over the globe. ART was implemented in the human and animal due to the non-occurrence of the childbirth. This has drastically has been impacted due to the fear and issued certain guidelines to avoid the contact of corona-virus infection on a child’s birth all over the world. For example recently in 2020, the American Society for Reproductive Medicine (ASRM) has suggested stopping the new treatment cycle using methods like in vitro fertilization (IVF) for childbirth and issued new guidelines to avoid infection.

Key Vendor Takeaway

The leading players of the global ART market include Anecova, OvaScience, Merck KGaA, Parallabs, California Cryobank, Bloom IVF Centre, Cooper Surgical, Origio, European Sperm Bank, Microm Ltd., Ferring Pharmaceuticals, and Hamilton Throne Limited.

Companies are actively involved in strategic joint ventures, mergers, and acquisitions to capture a large customer base. For instance, in November 2019, INVO Bioscience entered into new distribution agreements in the continent of Africa (covering Uganda, Nigeria, Sudan, and Ethiopia) to commercialize the INVOcell-In Vivo Fertilization System. This agreement helped the company to enter into the highly populated and underserved infertility markets in the African region.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2026
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET KEY PLAYERS

OvaScience
Merck KGaA
Parallabs
Bloom IVF Centre
Cooper Surgical
Origio
Microm UK Ltd
Ferring Pharmaceuticals
Irvine Scientific
European Sperm Bank
GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET, BY PROCEDURE

Frozen Donor
Frozen Non-donor
Fresh Donor
Fresh Non-Donor
Embryo/Egg Banking
GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET, BY TECHNOLOGY

In-Vitro Fertilization (IVF)
IVF with Intracytoplasmic Sperm Injection (ICSI)
IVF without Intracytoplasmic Sperm Injection (ICSI)
Others
GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET, BY REGION

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA